The aim of our study was to assess the effect of methylene blue infusion on plasma levels of cytokines in severe sepsis.
Sepsis is defined as the systemic response to infection 1, 2 . The deleterious effect of bacterial invasion of body tissues results from the combined action of enzymes and toxins, produced by the microorganisms themselves, and by endogenous cells in response to the infectious process. Nitric oxide (NO) is produced (constitutively) in blood vessel walls by the enzyme NO synthetase (NOS), at which point it acts to control vascular tone 3 . Under normal conditions small amounts of NO are formed from L-arginine by the constituent NOS present in the vascular endothelium. Upon stimulation by endotoxin and cytokines, an inducible calcium-independent isoform of NOS is formed in various cell types. This inducible enzyme differs from the constitutive isoform in that it releases massive amounts of NO over a long time period, resulting in profound vasodilatation, hypotension and resistance to catecholamines 4 . After activation of the soluble guanylate cyclase in smooth muscle cells, NO increases the generation of cyclic guanosine monophosphate (cGMP).
Theoretically, inhibition of excessively produced NO could act favourably by preventing systemic vasodilatation and reducing microvascular injury in endotoxaemic subjects 5, 6 . Methylene blue, a combined non-selective inhibitor of soluble guanylate cyclase and NOS, has been studied in endotoxaemic animals and patients with septic shock 7, 8 . Administered as bolus injections, methylene blue decreases the plasma levels of the stable NO metabolites, nitrites and nitrates as well as cGMP. Several uncontrolled investigations on patients with septic shock requiring adrenergic support also indicate that methylene blue, administered as a bolus or short-term infusion, restores mean arterial pressure (MAP) by increasing systemic vascular resistance. Moreover, methylene blue improves myocardial contractility and oxygen delivery [9] [10] [11] [12] [13] .
Since methylene blue has been shown to reduce the endotoxin-induced tumour necrosis factor α (TNF-α) synthesis in Kupffer cells, it is conceivable that methylene blue decreases the detrimental effects of cytokines 14 . In pathogenesis of sepsis, TNF-α and interleukin (IL)-1β are the first two cytokines involved 15 . IL-6 is released into the bloodstream after any kind of tissue insult but highest serum concentrations are reached during sepsis 16 . In animal or human endotoxaemia models, both IL-8, which is one of the most powerful chemoattractive agents for neutrophils and IL-6 were found in the bloodstream after the peaks of TNF-α and IL-1β concentrations were reached [17] [18] [19] .
The purpose of the present study was to evaluate the effects of continuously infused methylene blue on serum cytokine levels in humans suffering from severe sepsis.
MATERIALS AND METHOD Patient Population and Study Design
The Regional Committee on Medical Research Ethics approved the study. Written informed consent was obtained from the patients wherever possible, or from the next of kin. Critically ill patients with bacteriologically-documented infections were included in the study as soon as they met at least two of the following criteria of sepsis, defined by the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee 2 : temperature of >38°C or <36°C; heart rate of >90 beats.min -1 ; respiratory of >20 breaths.min -1 or P a CO 2 of <32 mmHg; and leukocyte count of >12x10 9 .l -1 or <4x10 9 .l -1 . In addition, at least one of following conditions was required: hypoxaemia (P a CO 2 /FiO 2 of <250); oliguria (urine output of <0.5 ml.kg -1 body weight for 2 h); lactic acidosis (lactate concentration of >2 mmol.l -1 ); thrombocytopenia (platelet count of <100x10 9 .l -1 ) or a recent change in mental status without sedation. Patients who were <18 years of age, pregnant, or receiving corticosteroids, immunosuppressants or chemotherapy, and those with a known irreversible underlying disease, such as end-stage neoplasm, were excluded.
The acute physiology and chronic health evaluation (APACHE II) 20 and sepsis-related (or sequential) organ failure assessment (SOFA) 21 scores were employed to determine the initial severity of illness.
If required, patients underwent surgical procedures before the start of the study. No invasive surgery or renal operative procedures were performed during the 48 h study period. All patients were ventilated in volume-controlled mode (Puritan Bennett 7200, Carlsbad, CA) and received continuous sedation and analgesia with midazolam and fentanyl. Ventilator settings and levels of positive end-expiratory pressure and fractional inspired oxygen were kept constant during methylene blue or placebo infusion. Antibiotic treatment was adjusted according to bacteriological culture results such as blood culture or samples taken from different sites of the body. In all subjects fluid replacement was administered to keep the central venous pressure (CVP) between 4 and 8 mmHg. During the study no inotropic agent was administered. Those patients who met the above criteria for severe sepsis were enrolled into the study within four hours of ICU admission.
Protocol
Randomization was achieved according to computer-steered permuted block design. The study was a prospective, randomized, double-blind, placebocontrolled study. To perform the study in a doubleblind protocol, drug solution and infusion set were covered with foil, and administered to all patients by a nurse without knowledge of the study protocol. The follow-up was done by an anaesthetist without knowledge of the study protocol. The patients were given methylene blue (Methylenblau VITIS® %1, Neopharma GmbH & Co. KG, Aschau i. Chiemgau, Germany) (n=15, group MB) or a corresponding volume of isotonic saline (n=15, control group). Methylene blue was diluted with total 100 ml isotonic saline and administered via a dedicated central venous catheter by continuous infusion of 0.5 mg.kg -1 .h -1 over 6 h. In the control group, patients were given 100 ml isotonic saline over 6 h.
Measurements
All patients had arterial catheters (arterial line kit:Abbott, monitoring kit: Transpac® IV, Sligo, Ireland) and central venous catheters via subclavian (Braun, Certofix trio V 720 7Fx8", Melsungen, Germany) in place. Arterial blood samples were simultaneously withdrawn for measurements of pH, PO 2 , PCO 2 and SaO 2 (Medica Easy BloodGas, Massachusetts, U.S.A.). CVP, MAP, heart rate (HR) and nasopharyngeal temperature were monitored continuously (SpaceLabs Inc., Redmond, U.S.A.). Methaemoglobin concentrations were obtained at baseline (15 min before start of the study) and repeated immediately after, and at 24 and 48 hours after methylene blue infusion. Platelets, leukocytes, bilirubin, alanine aminotransferase and creatinine were determined at the same time-points (Vitalab Flexor, Dieren, Netherlands).
TNF-α, IL-1β, IL-2 receptor, IL-6, and IL-8 levels were measured at the same times. Venous blood was collected into a 10 ml sterile plain tube (without anticoagulant) before administration of any medications and stored at -20°C. Before assay, all samples were thawed to room temperature and mixed by gentle swirling or inversion. All sera were assayed on the same day to avoid interassay variation. TNF-α, IL-1, IL-2 receptor, IL-6, IL-8 levels were measured with a solid-phase, two-site chemiluminescent enzyme immunometric assay method (IMMULITE TNF-α, IMMULITE IL-1β, IMMULITE IL-2 RECEPTOR, IL-6 IMMULITE, and IL-8 IMMULITE, EURO/ DPC, Llanberis, U.K.). The antibodies used in this procedure have no known cross-reactivities with other cytokines. For IL-1β, the intra-assay and interassay coefficient variation of this procedure was 2.8%-4.9% and 4.8%-9.1%, respectively. For IL-2 receptor, the intra-assay coefficient variation of this procedure was 2.9%-3.7% and the interassay coefficient variation was 6.1%-8.1%. For IL-6, the intraassay and interassay coefficient variation of this procedure was 3.6%-6.2% and 5.4%-9.6%, respectively. For IL-8, the intra-assay and interassay coefficient variation of this procedure was 3.6%-3.8% and 5.2%-7.4%, respectively. For TNF-α, the intra-assay and interassay coefficient variation of this procedure was 2.6%-3.6% and 4.0%-6.5%, respectively. The lowest detectable limits of IL-1β, IL-2 receptor, IL-6, IL-8, and TNF-α, were 1.5 pg.ml -1 , 5 U.ml -1 , 5 pg.ml -1 , 2 pg.ml -1 and 1.7 pg.ml -1 respectively.
Duration of mechanical ventilation was recorded. Survival was defined as being alive at hospital discharge.
Statistics
Repeated measures ANOVA test was used to evaluate the differences between and within groups toward the baseline values. In case of the presence of any significance, the groups were tested by independent sample t-test to determine which difference was significant. Data were expressed as mean±SD. A P value of <0.05 was considered significant.
RESULTS

Patient Characteristics
Clinical and demographic characteristics of the patients were listed on 
Haemodynamic Parameters, Oxygen Transport Variables
There was no significant difference between the groups with respect to pH, P a O 2 , P a CO 2 , P a O 2 /FiO 2 ratio and SaO 2 (P>0.05). At the completion of the methylene blue infusion, MAP was significantly increased from baseline (P<0.001). It was also significantly higher than the control group (P<0.05). No significant change in HR was found in either group (Table 2) . Towards the end of the methylene blue infusion, methaemoglobin concentration increased significantly (P<0.05). It was also significantly higher than the control group (P<0.05). In biochemical parameters, there was no significant difference between the groups (Table 3 ) (P>0.05).
Outcome
Outcomes are listed in Table 1 . The overall hospital mortality rate was similar in both groups (26.6%). All non-survivors died while being mechanically ventilated. Mean survival time was 7±3 days in the MB group, and 7±4 days in the control group. The duration of mechanical ventilation and ventilator-free days (calculated as the number of days a patient was alive and without mechanical ventilation at 28 days) was the same in both groups. In the methylene blue and placebo groups, ventilation duration was 7±2 and 8±3 days respectively (P>0.05) and ventilatorfree days, 11±3 and 10±3 days respectively (P>0.05).
The ICU stay of methylene blue treated survivors was not significantly different from that of the placebo treated survivors (13±2 vs 16±4 days), (P>0.05).
Plasma Cytokine Levels
TNF-α, IL-1β, IL-2 receptor, IL-6, and IL-8 levels remained unchanged during the study (Table 4 ).
Side-effects
Except for a blue colouration of the urine, no sideeffects were noted during or after administration of methylene blue. Towards the end of methylene blue infusion, methaemoglobin concentration, in comparison to its own intragroup baseline and to the control group, increased significantly, but decreased to the baseline concentration at 24 h.
DISCUSSION
Methylene blue, a combined nonselective inhibitor of soluble guanylate cyclase and NOS 7, 8 , has been studied in endotoxaemic animals and patients with septic shock. To inhibit the L-arginine 4 nitric oxide pathway several agents are used, including specific competitive L-arginine antagonists, or less specific NOS inhibitors such as dexamethasone 9 . Since methylene blue is a strong inhibitor of guanylate cyclase, the target enzyme of NO, we used it in this study. Some studies have assessed the acute effects of methylene blue on haemodynamics and gas exchange in patients with refractory septic shock. Haemodynamic and respiratory parameters were measured after an IV bolus injection of methylene blue 1 mg.kg -1 , and it was found that this had an acute vasopressor effect in patients with refractory septic shock, and that it was not deleterious to respiratory function 12 . Cheng and Pang 22 , examined the effects of methylene blue on MAP, cardiac output, total peripheral resistance, mesenteric blood flow and renal blood flow in rats. Methylene blue was infused intravenously at 1, 3 or 10 mg.kg -1 .h -1 . They found that while a low dose of methylene blue increased MAP and total peripheral resistance, and did not alter cardiac output, a high dose of methylene blue did not raise MAP but increased total peripheral resistance and reduced cardiac output. Preiser et al 13 found that in septic shock patients, while the administration of methylene blue 2 mg.kg -1 IV resulted in a transient and reproducible increase in arterial pressure associated with an improvement in cardiac function, it did not increase oxygen delivery. These effects may be attributed to inhibition of excessive NO/cGMP generation, restoration of the vascular sensitivity to catecholamines and counteraction of myocardial depression. Administered as bolus injection, methylene blue decreases the plasma levels of the stable NO metabolites, nitrites and nitrates as well as cGMP. Consequently, methylene blue transiently restores MAP by increasing systemic vascular resistance and improving myocardial function, the latter at variance from other inhibitors of NOS 6, 13, [23] [24] [25] [26] . Moreover, methylene blue attenuates morphologic signs of lung injury and delays mortality in rats after bowel perforation 14 . In contrast to the above-mentioned beneficial effects, administration of methylene blue has also been reported to increase mean pulmonary arterial pressure and total pulmonary vascular resistance 13, 24, 25 . Most likely, this effect is caused by a decrease in basal NO/cGMP production in the pulmonary vasculature.
Some authors, however, found in experimental studies that NOS inhibition had less beneficial effect [27] [28] [29] [30] . Klabunde and Ritger 27 reported an increase in arterial pressure but a reduction in CO. In some studies, NO blockade was even detrimental, since it worsened the haemodynamic status and increased mortality [28] [29] [30] . These differences may be related to the experimental model, the type of NO blockade, the dose used and the timing of this intervention.
Continuous infusion of methylene blue has only been described in endotoxaemic sheep and in two studies in patients with septic shock 10, 11, 31 . Kirov et al 11 evaluated the effect of continuous infusion of methylene blue on haemodynamics and organ function in human septic shock. They found that continuously infused methylene blue (IV bolus injection of 2 mg.kg -1 followed 2 h later by an infusion at stepwise increasing rates of 0.25, 0.5, 1 and 2 mg.kg -1 .h -1 ) each maintained for one hour counteracted myocardial depression, maintained oxygen transport and reduced concurrent adrenergic support, and the infusion of methylene blue appeared to have no significant adverse effects on various organ functions. Brown et al 31 reported a beneficial haemodynamic effect of continuous infusion of methylene blue during sepsis. Evgenov et al 10 found that during the early phase of endotoxaemia in sheep, methylene blue infusion (2.5 mg.kg -1 .h -1 for 5 h) attenuated lung injury by decreasing the enhanced lung fluid filtration as a result of reduced pulmonary capillary pressure and permeability.
Sepsis and septic shock remain as major causes of death in ICUs. Complications of sepsis have been related to an intense host response based on a delicate equilibrium between various pro-and antiinflammatory mediators 33 . An overwhelming production of pro-inflammatory cytokines, such as TNF-α, IL-1β, IL-2R, IL-6, and IL-8 may induce biochemical and cellular alterations either directly or by orchestrating secondary inflammatory pathways. These include the recruitment and activation of granulocytes and macrophages, enhancement of cell adhesion, induction of NOS, and activation of phospholipase. In a recent study on cultured rat cardiac myocytes exposed to TNF-α, IL-1β, and serum from septicaemic patients, methylene blue prevented myocyte depression and restored myocyte-shortening velocity 34 . Since methylene blue has also been shown to reduce the endotoxin-induced TNF-α synthesis in Kupffer cells, it is conceivable that methylene blue counteracts the detrimental effects of this cytokine on other target organs as well, including the heart 15 .
Kirov et al 11 found that TNF-α levels have a tendency to reduce in the methylene blue group compared with controls, but this was not significant. Cytokine levels in the plasma do not necessarily reflect the local synthesis of cytokines by cells. Many cells have surface receptors for these cytokines with high binding properties, and target cells and soluble receptors trap cytokines. Thus cytokines released at the local level may remain undetected in the plasma. In our study, we found that plasma cytokine levels remained unchanged during a period of 48 hours.
Methylene blue has no major toxicity. A total accumulated dose of 5.75 mg.kg -1 for continuous infusion was recommended in septic shock 31 . Higher doses can be associated with methaemoglobinaemia. Thus, we used a dose of 0.5 mg.kg -1 .h -1 in the present study. However, in our study methylene blue infusion resulted in a marked elevation of plasma methaemoglobin immediately after the infusion, then rapidly decreasing to baseline values. In accord with other studies 11, 25 , we did not find an increase in plasma methaemoglobin levels at 24 and 48 h.
Methylene blue results in an increase in procoagulant activity most likely caused by inhibition of the anti-aggregatory effect of endothelial cGMP 35 . Methylene blue influences the febrile reaction by modulation of the interaction between NO and the cyclo-oxygenase pathway or through reduced generation of oxygen free radicals 36, 37 . Kirov et al 11 found that the platelet count demonstrated a trend to a larger reduction in the methylene blue group, and that the body temperature decreased at 24 h. We did not observe any side effect. The different results in our study could be related to the use of a lower dose of methylene blue.
To our knowledge, no other study has investigated the effect of methylene blue infusion on cytokine release in severe sepsis in humans. We found no change in either cytokine levels or patient outcome. The administration of methylene blue resulted in a transient increase in mean arterial pressure. Because of the limited number of patients in our study and the short period of observation, our findings need to be confirmed by larger clinical trials of methylene blue infused in a dose-titrated manner.
